Bononi et al. reported that MM initiation is linked to metabolic reprogramming [14], and Zhang et al. also revealed that metabolic enzymes, such as SLC7A11, might serve as treatment targets for MM [15]. The gene discussed is SLC7A11; the disease is Miyoshi myopathy.